JOHNSTOWN, Pa., March 16, 2016 -- Concurrent Technologies Corporation's (CTC's) Edward J. Sheehan, Jr., President & CEO, will deliver a keynote address at the National Contract Management Association's (NCMA's) 2016 Subcontract Management Training Forum, which takes place March 17–18, 2016, in Tysons, Virginia. The forum highlights government, commercial, and supply chain knowledge and best practices. Attendees will gain specific insight into overcoming today's challenges and have an opportunity to network with supply chain leaders and 200 other professional buyers specifically involved in the subcontract management community.
"The Subcontract Management Training Forum brings together people from over 150 organizations in government and industry to discuss the challenges regarding subcontract management," said Mr. Sheehan. "As our industry continues to evolve and contract requirements change, it is important to have policies and procedures in place for managing subcontractors."
Lynne Hood, CTC Senior Director, Procurement & Subcontracts, and Mindy Schreyer-Hughes, CTC Government Liaison Lead, are also participating in the forum by leading a breakout session. "Closeout Policies & Practices…Getting It Done Efficiently." The discussion will highlight how to quickly close out numerous transactions within quick timeframes.
The National Contract Management Association (NCMA), founded in 1959, is the world's leading professional resource for those in the field of contract management. The organization, which has over 20,000 members, is dedicated to the professional growth and educational advancement of procurement and acquisition personnel worldwide. NCMA strives to serve and inform the profession it represents and to offer opportunities for the open exchange of ideas in neutral forums.
Concurrent Technologies Corporation (CTC) is an independent, nonprofit, applied scientific research and development professional services organization. Together with our affiliates, Enterprise Ventures Corporation and CTC Foundation, we leverage research, development, test and evaluation work to provide transformative, full lifecycle solutions. To best serve our clients' needs, we offer the complete ability to fully design, develop, test, prototype, and build. We support our clients' core mission objectives with customized solutions and strive to exceed expectations. CTC has been named one of the World's Most Ethical Companies by Ethisphere Institute, the global leader in defining and advancing the standards of ethical business practices. In addition, CTC has been named a Best for Vets Employer by Military Times. For more information about CTC, visit www.ctc.com.
CONTACT: Media Contact: Mary Bevan
814-269-2490 or [email protected]


Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 



